PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.
NORTH BILLERICA, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging ...
PSMA PET/CT accurately detects recurrent prostate cancer in 67-year-old man. 18F-DCFPyL-PSMA PET/CT shows extensive, intensely PSMA-avid local recurrence in prostate (bottom row; solid arrow) in ...
Patient undergoing PET/CT Investigators zero in on which patients might benefit most from PSMA-PET-guided salvage radiation therapy for post-RP recurrent prostate cancer. Study findings presented at ...
NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., a global leader ...
Prostate cancer cells have high levels of prostate-specific membrane antigen (PSMA), but researchers were unsure of its biological role. Now an MSK-led team has discovered that PSMA contributes to ...
New prostate cancer research shows that adding an interim scan during therapy can help guide a patient's treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging ...
Two novel radiolabeled small molecules targeting prostate-specific membrane antigen have excellent potential for further development as diagnostic and therapeutic radiopharmaceuticals, according to ...
The novel radiopharmaceutical 18F-PSMA-1007 is both effective and readily available for detecting malignant prostate cancer lesions, according to research published in the April issue of The Journal ...
Prostate-specific membrane antigen (PSMA) is a protein found in small amounts in your prostate gland. When you have prostate cancer, you have many times more PSMA than normal. This makes PSMA a good ...
A novel targeted radionuclide therapy has shown promising clinical activity and low toxicity in a group of heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC). The ...
New prostate cancer research shows that adding an interim scan during therapy can help guide a patient's treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback